Characterisation and outcome of RAC1 mutated melanomaGeorg Lodde, Klaus Griewank, Lea Jessica Albrecht et al.|European Journal of Cancer|2023Cited by 14
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patientsGeorg Lodde, Jürgen C. Becker, Ulrike Leiter et al.|European Journal of Cancer|2025Cited by 9
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg Lodde, Selma Ugurel, Fang Zhao et al.|European Journal of Cancer|2024Cited by 9
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasPhilipp Jansen, Klaus Griewank, Wolfgang Galetzka et al.|European Journal of Cancer|2024Cited by 4
Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanomaGeorg Lodde, Elisabeth Livingstone, J. Dollani et al.|British Journal of Dermatology|2025Cited by 3